Sri Lanka joins the CAPTIVATE trial

We are proud to announce that Sri Lanka is now part of the groundbreaking CAPTIVATE trial, a global initiative aimed at finding the best treatment, or combination of treatments to slow the progression of chronic kidney disease (CKD) so that fewer people develop kidney failure. The trial is sponsored by The George Institute for Global Health and National Health and Medical Research Council (NHMRC). CAPTIVATE is a multi-centre, phase III, adaptive, platform, randomised controlled trial. https://campaigns.georgeinstitute.org/t/t-D9089E84C38755AF2540EF23F30FEDED

CAPTIVATE is the first platform trial in CKD and will identify the best treatments for CKD more quickly than with traditional trial designs, thus saving time and money.

The CAPTIVATE national lead in Sri Lanka is Professor Asita de Silva and the regional coordinating centre is RemediumOne. RemediumOnes’ role in CAPTIVATE includes site management, patient recruitment and retention, data management, and regulatory support. This trial not only highlights Sri Lanka’s growing contribution to global health research but also reinforces our commitment to improving outcomes for patients with chronic kidney disease.

Key facts

The trial is ‘eternal’, which means that participants will continue to be recruited for many years until the trial is finally wound up.
It is also ‘adaptive’, providing the flexibility to add new treatments, or remove those that are not working.
CAPTIVATE will begin by testing whether a mineralocorticoid receptor antagonist slows the progression of CKD when compared to placebo.
Participants can participate in more than one treatment at the same time or at different times.
Participants receive each study treatment for 2 years. For each treatment, participants are followed up at study visits that occur at approximately one month, 3 months, 6 months, 12 months, 18 months and 2 years after starting treatment. A final study visit occurs one month after the end of the 2-year treatment phase.
Information collected at study visits includes blood and urine test results, safety assessments and treatment adherence. Information about the overall health status of each participant is collected every 5 years.
1000 participants will be recruited globally from over 50 sites in Australia, New Zealand, Sri Lanka, India and Italy. Additional treatments, participants, countries and sites will be added as the trial grows.
To date, 53 participants have been randomised across 3 countries.

Stay tuned for updates on the CAPTIVATE trial and our continued efforts to advance clinical research in Sri Lanka and beyond.

https://campaigns.georgeinstitute.org/t/t-D9089E84C38755AF2540EF23F30FEDED